Pfizer (PFE) Competitors $24.94 -0.16 (-0.64%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends PFE vs. JNJ, ABBV, MRK, BMY, ZTS, RPRX, JAZZ, CORT, PRGO, and SUPNShould you be buying Pfizer stock or one of its competitors? The main competitors of Pfizer include Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Corcept Therapeutics (CORT), Perrigo (PRGO), and Supernus Pharmaceuticals (SUPN). These companies are all part of the "pharmaceuticals" industry. Pfizer vs. Johnson & Johnson AbbVie Merck & Co., Inc. Bristol-Myers Squibb Zoetis Royalty Pharma Jazz Pharmaceuticals Corcept Therapeutics Perrigo Supernus Pharmaceuticals Pfizer (NYSE:PFE) and Johnson & Johnson (NYSE:JNJ) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, community ranking, dividends, risk, earnings, media sentiment and valuation. Which has more risk & volatility, PFE or JNJ? Pfizer has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500. Is PFE or JNJ more profitable? Johnson & Johnson has a net margin of 19.14% compared to Pfizer's net margin of 7.07%. Johnson & Johnson's return on equity of 35.45% beat Pfizer's return on equity.Company Net Margins Return on Equity Return on Assets Pfizer7.07% 16.28% 6.68% Johnson & Johnson 19.14%35.45%14.23% Does the media prefer PFE or JNJ? In the previous week, Johnson & Johnson had 9 more articles in the media than Pfizer. MarketBeat recorded 87 mentions for Johnson & Johnson and 78 mentions for Pfizer. Johnson & Johnson's average media sentiment score of 1.20 beat Pfizer's score of 0.92 indicating that Johnson & Johnson is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pfizer 38 Very Positive mention(s) 8 Positive mention(s) 19 Neutral mention(s) 5 Negative mention(s) 4 Very Negative mention(s) Positive Johnson & Johnson 65 Very Positive mention(s) 6 Positive mention(s) 13 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals believe in PFE or JNJ? 68.4% of Pfizer shares are held by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are held by institutional investors. 0.1% of Pfizer shares are held by company insiders. Comparatively, 0.2% of Johnson & Johnson shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has preferable earnings & valuation, PFE or JNJ? Johnson & Johnson has higher revenue and earnings than Pfizer. Johnson & Johnson is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPfizer$59.38B2.38$2.12B$0.7433.71Johnson & Johnson$85.16B4.33$35.15B$6.9122.16 Do analysts rate PFE or JNJ? Pfizer presently has a consensus price target of $32.92, indicating a potential upside of 31.98%. Johnson & Johnson has a consensus price target of $175.94, indicating a potential upside of 14.92%. Given Pfizer's higher possible upside, analysts plainly believe Pfizer is more favorable than Johnson & Johnson.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pfizer 1 Sell rating(s) 8 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 2.50Johnson & Johnson 0 Sell rating(s) 7 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.53 Is PFE or JNJ a better dividend stock? Pfizer pays an annual dividend of $1.68 per share and has a dividend yield of 6.7%. Johnson & Johnson pays an annual dividend of $4.96 per share and has a dividend yield of 3.2%. Pfizer pays out 227.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Johnson & Johnson pays out 71.8% of its earnings in the form of a dividend. Pfizer has increased its dividend for 15 consecutive years and Johnson & Johnson has increased its dividend for 63 consecutive years. Does the MarketBeat Community prefer PFE or JNJ? Pfizer received 392 more outperform votes than Johnson & Johnson when rated by MarketBeat users. Likewise, 69.04% of users gave Pfizer an outperform vote while only 65.16% of users gave Johnson & Johnson an outperform vote. CompanyUnderperformOutperformPfizerOutperform Votes150569.04% Underperform Votes67530.96% Johnson & JohnsonOutperform Votes111365.16% Underperform Votes59534.84% SummaryJohnson & Johnson beats Pfizer on 15 of the 22 factors compared between the two stocks. Ad Weiss RatingsTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. Get Pfizer News Delivered to You Automatically Sign up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PFE vs. The Competition Export to ExcelMetricPfizerPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$141.36B$6.45B$5.04B$19.88BDividend Yield6.77%8.11%5.16%3.52%P/E Ratio33.7110.78130.5342.95Price / Sales2.38243.701,183.8619.18Price / Cash8.3322.1633.6117.86Price / Book1.585.474.685.52Net Income$2.12B$153.61M$119.23M$986.45M7 Day Performance-4.13%-2.00%-1.83%0.45%1 Month Performance-13.77%-7.46%-3.61%1.05%1 Year Performance-17.70%31.82%31.74%24.67% Pfizer Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PFEPfizer5 of 5 stars$24.95-0.6%$32.92+32.0%-16.8%$142.24B$58.50B33.7188,000Analyst DowngradeAnalyst RevisionJNJJohnson & Johnson4.9618 of 5 stars$153.10+0.1%$175.94+14.9%+2.1%$368.37B$87.70B22.16131,900Positive NewsABBVAbbVie4.9604 of 5 stars$167.74+0.7%$203.37+21.2%+21.3%$296.42B$54.32B58.2450,000Analyst ForecastPositive NewsMRKMerck & Co., Inc.4.9964 of 5 stars$97.43+0.9%$130.86+34.3%-5.1%$246.46B$60.12B20.4372,000Dividend IncreasePositive NewsBMYBristol-Myers Squibb4.7747 of 5 stars$57.88-0.6%$54.07-6.6%+18.4%$118.10B$47.44B-16.1234,100Analyst RevisionZTSZoetis4.8582 of 5 stars$175.67+0.1%$221.44+26.1%-0.2%$79.21B$8.54B33.0214,100Positive NewsRPRXRoyalty Pharma4.7172 of 5 stars$26.22+0.8%$41.67+58.9%-2.6%$15.32B$2.36B13.5980JAZZJazz Pharmaceuticals4.9172 of 5 stars$119.24+2.1%$175.53+47.2%-1.2%$7.06B$3.99B16.792,800Analyst ForecastCORTCorcept Therapeutics4.6651 of 5 stars$56.09+3.3%$65.25+16.3%+116.2%$5.88B$482.38M44.52300PRGOPerrigo4.9792 of 5 stars$27.15-0.3%$37.00+36.3%-10.8%$3.72B$4.66B0.009,140Positive NewsSUPNSupernus Pharmaceuticals2.3042 of 5 stars$36.12+1.7%$36.00-0.3%+32.3%$1.96B$607.52M33.76580Positive News Related Companies and Tools Related Companies Johnson & Johnson Alternatives AbbVie Alternatives Merck & Co., Inc. Alternatives Bristol-Myers Squibb Alternatives Zoetis Alternatives Royalty Pharma Alternatives Jazz Pharmaceuticals Alternatives Corcept Therapeutics Alternatives Perrigo Alternatives Supernus Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:PFE) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pfizer Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pfizer With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
